Evaluation of the efficacy and safety of rosuvastatin 5 mg versus pravastatin 40 mg and atorvastatin 10 mg in type IIa and IIb hypercholesterolaemic patients - CAP-Chol

Exclusion Criteria

• - homozygous or heterozygous familial hypercholesterolaemia
• - hypertriglyceridaemia (TG ≥ 4 g/l)
• - subjects at high cardiovascular risk according to the AFSSAPS 2005 definition (coronary artery disease or history of documented vascular disease, high cardiovascular risk type 2 diabetes, subject in primary prevention with a 10-year CHD risk > 20%)
• - history of adverse events or hypersensitivity to an HMG Co-A reductase inhibitor (particularly a history of myopathy)
• - concomitant use of any drugs not authorized during the study
• - active liver disease with elevation of serum transaminases (ASAT, ALAT) more than twice the upper limit of normal
• - CPK more than 3 times the upper limit of normal
• - moderate or severe renal failure (creatinine clearance < 6 ml/min)
• - poorly controlled hypothyroidism; poorly controlled hypertension (DBP > 95 mm Hg and/or SBP > 180 mm Hg)